STAT3 and neoplasm: JAK inhibitors AG490 [166,198], WP1066 [168,169], TG101209 [170] and AZD1480 [171,172] reduce the level of STAT3 phosphorylation, resulting in multiple anticancer effects such as decreased tumor growth, increased apoptosis, and reduced metastasis.